Debate: Should the dose or duration of anticoagulants for the prevention of venous thrombosis be increased in patients with COVID-19 while we are awaiting the results of clinical trials?

Br J Haematol. 2021 Feb;192(3):459-466. doi: 10.1111/bjh.17241. Epub 2020 Nov 25.

Authors

Keith Gomez¹, Mike Laffan², Charlotte Bradbury^{3

4}

Affiliations

¹ Haemophilia Centre and Thrombosis Unit, Royal Free Hospital London NHS Foundation Trust, London, UK.
² Department of Immunity and Inflammation, Centre for Haematology, Faculty of Medicine, Imperial College London, London, UK.
³ Faculty of Translational Health Sciences, University of Bristol, Bristol, UK.
⁴ University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

No abstract available

Keywords: anticoagulation; clinical trials; coronavirus disease 2019; thromboprophylaxis; venous thrombosis.

Publication types

Letter

MeSH terms

Anticoagulants / administration & dosage*
COVID-19 / complications*
COVID-19 / virology
Clinical Decision-Making
Clinical Trials as Topic
Disease Management
Disease Susceptibility
Duration of Therapy
Humans
SARS-CoV-2*
Venous Thrombosis / etiology
Venous Thrombosis / prevention & control*

Substances

Anticoagulants